objective of this study is to 1) describe a novel HPV-positive LSCC cell line and 2) report the prevalence of HPV-positive LSCC in a select patient population.
Head and Neck Surgery Prospective Evaluation of the McGill thyroid Nodule Score
Yalon Dolev, MD (presenter); Michael P. Hier; Michael Tamilia, MD, FRCP; Richard J. Payne, MD, FRCS Objective: 1) Familiarize the audience with the new McGill Thyroid Nodule Score (MTNS) scoring system for thyroid nodules. 2) Present the statistics on the MTNS and why we feel this is a great adjunct in the management of thyroid nodules. 3) Describe a new tool at the clinician's disposal that will help better manage patients with thyroid nodules.
Method: This is a prospective study. A total of 245 consecutive patients were enrolled between July 2009 and March 2011. McGill Thyroid Nodule Score (MTNS), age, gender, and extent of surgery were recorded preoperatively. Final pathology was recorded postthyroidectomy. The percentage of malignancy was calculated for each MTNS score. Using Fisher exact test, the risk of malignancy for each group was compared to that anticipated based on the MTNS. We then used linear regression to plot a best fit curve for both the retrospective and prospective data and compared the 2.
Results:
We found no statistically significant difference when comparing the risk of malignancy between the retrospective group originally used to create the MTNS and the prospective group used to validate this tool with P > .05 for all groups. Regression analysis revealed linear curves and also showed no significant difference between both groups (P = .35).
Conclusion:
The MTNS system has been validated prospectively and is a unified and individualized tool to help clinicians with multiple aspects in the management of patients with thyroid nodules. This includes discussion with patients regarding the risk of their nodules harbouring malignancy, decisions regarding extent of surgery, and discussion between physicians.
Head and Neck Surgery Protection of Radiotherapy-induced Xerostomia with Vitamin E+C Complex
Ki-Nam Park (presenter); Young-Ik Son, MD, PhD; Chung Hwan Baek Objective: Salivary tissues are easily damaged by radiotherapy (RT) and therefore xerostomia becomes the most common complaint in patients who receive RT in the head and neck area. This study aimed to elucidate the effective of antioxidant vitamin E and C complex on the protection of RT-induced xerostomia.
Method: A trial group received a vitamin E (200 IU) + C (500 mg) complex for 3 months of peri-RT period. A control group took placebo which had no inner contents. Subjective questionnaires, objective grading by a nurse-specialist, and scintigraphs were obtained before and after 1 and 6 months of RT.
Results: Sixty-five patients were initially enrolled and 39 patients completed the study as scheduled. There were no differences in age, sex, RT dosage, tumor staging, and treatment modality between the 2 groups. The trial group reported less discomfort in 2 items of subjective evaluation; "impaired speech" and "difficulty of mastication" (P < .05). Pre-and poststimulatory oral salivary scan were higher in the trial group (P < .034 and P < .026, respectively). In the trial group, maximum accumulations in submandibular gland were significantly higher at 1 month as well as at 6 months after RT (P < .041 and P < .004, respectively).
Conclusion: Short-term administration of antioxidant vitamin E and C complex during the period of RT has protective roles against xerostomia. Higher oral activity in the trial (vitamin E+C) group is probably based on the protection of accumulatory function of the SMG.
Head and Neck Surgery Quality of Life of Head and Neck Cancer Patients in Ghana
Susannah E. Hills, MD (presenter); Mark E. Prince, MD Objective: 1) Investigate quality of life (QOL) of patients undergoing radiation therapy for head and neck cancer at
